ADO

Summary

ADO (2-aminoethanethiol dioxygenase, HGNC:23506) is a protein-coding gene on chromosome 10q21.3, encoding 2-aminoethanethiol dioxygenase (Q96SZ5). Plays a vital role in regulating thiol metabolism and preserving oxygen homeostasis by oxidizing the sulfur of cysteamine and N-terminal cysteine-containing proteins to their corresponding sulfinic acids using O2 as a cosubstrate.

Human thiol dioxygenases include cysteine dioxygenase (CDO; MIM 603943) and cysteamine (2-aminoethanethiol) dioxygenase (ADO; EC 1.13.11.19). CDO adds 2 oxygen atoms to free cysteine, whereas ADO adds 2 oxygen atoms to free cysteamine to form hypotaurine (Dominy et al., 2007 [PubMed 17581819]).

Source: NCBI Gene 84890 — RefSeq curated summary.

At a glance

• GWAS associations: 29
• Clinical variants (ClinVar): 28 total — 2 pathogenic
• MANE Select transcript: NM_032804

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23506
Approved symbol	ADO
Name	2-aminoethanethiol dioxygenase
Location	10q21.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14547
Ensembl gene	ENSG00000181915
Ensembl biotype	protein_coding
OMIM	611392
Entrez	84890

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000373783, ENST00000710287

RefSeq mRNA: 1 — MANE Select: NM_032804 NM_032804

CCDS: CCDS7266

Canonical transcript exons

ENST00000373783 — 1 exons

Exon	Start	End
ENSE00001461538	62804720	62808479

Expression profiles

Bgee: expression breadth ubiquitous, 291 present calls, max score 99.54.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.0849 / max 179.5809, expressed in 1807 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
105159	11.0125	1732
105156	7.7369	1779
105160	1.1648	701
105155	1.0628	732
105161	0.6846	376
105157	0.2340	82
105158	0.1893	68

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.54	gold quality
male germ cell	CL:0000015	98.96	gold quality
secondary oocyte	CL:0000655	98.40	gold quality
oocyte	CL:0000023	97.95	gold quality
endothelial cell	CL:0000115	96.55	gold quality
adult organism	UBERON:0007023	94.60	gold quality
inferior vagus X ganglion	UBERON:0005363	94.08	gold quality
germinal epithelium of ovary	UBERON:0001304	93.94	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.71	gold quality
subthalamic nucleus	UBERON:0001906	93.44	gold quality
hair follicle	UBERON:0002073	93.42	gold quality
substantia nigra pars reticulata	UBERON:0001966	93.06	gold quality
substantia nigra pars compacta	UBERON:0001965	92.74	gold quality
dorsal plus ventral thalamus	UBERON:0001897	91.91	gold quality
CA1 field of hippocampus	UBERON:0003881	91.29	gold quality
epithelial cell of pancreas	CL:0000083	91.06	gold quality
superficial temporal artery	UBERON:0001614	91.00	gold quality
postcentral gyrus	UBERON:0002581	90.91	gold quality
choroid plexus epithelium	UBERON:0003911	90.90	gold quality
parietal lobe	UBERON:0001872	90.78	gold quality
spinal cord	UBERON:0002240	90.71	gold quality
pons	UBERON:0000988	90.69	gold quality
trigeminal ganglion	UBERON:0001675	90.58	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.48	gold quality
medulla oblongata	UBERON:0001896	90.44	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.14	gold quality
mucosa of paranasal sinus	UBERON:0005030	90.05	gold quality
ventral tegmental area	UBERON:0002691	89.91	gold quality
dorsal root ganglion	UBERON:0000044	89.90	gold quality
inferior olivary complex	UBERON:0002127	89.90	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-GEOD-124858	no	64.07
E-ANND-3	no	2.88

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SP1

miRNA regulators (miRDB)

146 targeting ADO, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-4725-3P	99.96	69.53	2520

Literature-anchored findings (GeneRIF, showing 5)

• when endogenous expression of the human ADO ortholog C10orf22 in HepG2/C3A cells was reduced by RNA-mediated interference, hypotaurine production decreased (PMID:17581819)
• this study shows in human cells that ADO regulates RGS4/5 (regulator of G protein signaling) N-degron substrates, modulates G protein-coupled calcium ion signals and mitogen-activated protein kinase activity, and that its activity extends to other N-cysteine proteins including the angiogenic cytokine interleukin-32 (PMID:31273118)
• Variants in IL23R-C1orf141 and ADO-ZNF365-EGR2 are associated with susceptibility to Vogt-Koyanagi-Harada disease in Japanese population. (PMID:32437414)
• Characterization of the nonheme iron center of cysteamine dioxygenase and its interaction with substrates. (PMID:32601061)
• Crystal structure of human cysteamine dioxygenase provides a structural rationale for its function as an oxygen sensor. (PMID:34508780)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	adoa	ENSDARG00000042827
danio_rerio	adob	ENSDARG00000053571
mus_musculus	Ado	ENSMUSG00000057134
rattus_norvegicus	Ado	ENSRNOG00000070733
drosophila_melanogaster	CG7550	FBGN0035839

Protein

Protein identifiers

2-aminoethanethiol dioxygenase — Q96SZ5 (reviewed: Q96SZ5)

Alternative names: Cysteamine dioxygenase

All UniProt accessions (2): Q96SZ5, A0AA34QVG9

UniProt curated annotations — full annotation on UniProt →

Function. Plays a vital role in regulating thiol metabolism and preserving oxygen homeostasis by oxidizing the sulfur of cysteamine and N-terminal cysteine-containing proteins to their corresponding sulfinic acids using O2 as a cosubstrate. Catalyzes the oxidation of cysteamine (2-aminoethanethiol) to hypotaurine. Catalyzes the oxidation of regulators of G-protein signaling 4 (RGS4) and 5 (RGS5) and interleukin-32 (IL32).

Subunit / interactions. Monomer.

RefSeq proteins (1): NP_116193* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011051	RmlC_Cupin_sf	Homologous_superfamily
IPR012864	PCO/ADO	Family
IPR014710	RmlC-like_jellyroll	Homologous_superfamily

Pfam: PF07847

Enzyme classification (BRENDA):

• EC 1.13.11.19 — cysteamine dioxygenase (BRENDA: 15 organisms, 14 substrates, 22 inhibitors, 7 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

6 substrates with measured Km, best-characterized 6. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
3-MERCAPTOPROPIONIC ACID	5	1
CYSTEAMINE	0.001	1
HOMOCYSTEAMINE	0.83	1
MERCAPTOETHANOL	1.2	1
N-ACETYLCYSTEAMINE	0.71	1
O2	0.1	1

Catalyzed reactions (Rhea), 2 shown:

• cysteamine + O2 = hypotaurine + H(+) (RHEA:14409)
• N-terminal L-cysteinyl-[protein] + O2 = N-terminal S-hydroxy-S-oxy-L-cysteinyl-[protein] + H(+) (RHEA:70895)

UniProt features (30 total): strand 11, helix 6, mutagenesis site 3, binding site 3, sequence variant 3, region of interest 2, chain 1, cross-link 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
9DXV	X-RAY DIFFRACTION	1.6
9DXB	X-RAY DIFFRACTION	1.74
9DXU	X-RAY DIFFRACTION	1.74
7REI	X-RAY DIFFRACTION	1.78
9DMA	X-RAY DIFFRACTION	1.89
9NDU	X-RAY DIFFRACTION	1.98
8UAN	X-RAY DIFFRACTION	1.99
8U9J	X-RAY DIFFRACTION	2.02
9DY4	X-RAY DIFFRACTION	2.39

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96SZ5-F1	87.28	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 112; 114; 193

Post-translational modifications (1): 220–223

Mutagenesis-validated functional residues (3):

Position	Phenotype
87	moderate reduction in enzyme activity.
222	significant reduction in enzyme activity.
223	no significant reduction in enzyme activity.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-1614558	Degradation of cysteine and homocysteine
R-HSA-1430728	Metabolism
R-HSA-1614635	Sulfur amino acid metabolism
R-HSA-71291	Metabolism of amino acids and derivatives

MSigDB gene sets: 215 (showing top): FXR_IR1_Q6, GCM_MAP4K4, RRAGTTGT_UNKNOWN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, AAGCCAT_MIR135A_MIR135B, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, chr10q21, GGAMTNNNNNTCCY_UNKNOWN, CAGCTG_AP4_Q5, YY1_Q6, AGCGCTT_MIR518F_MIR518E_MIR518A, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_LEVELS, YY1_02, KEGG_TAURINE_AND_HYPOTAURINE_METABOLISM, GOBP_RESPONSE_TO_OXYGEN_LEVELS

GO Biological Process (1): cellular response to hypoxia (GO:0071456)

GO Molecular Function (7): iron ion binding (GO:0005506), cysteamine dioxygenase activity (GO:0047800), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen (GO:0016702), metal ion binding (GO:0046872), dioxygenase activity (GO:0051213)

GO Cellular Component (2): mitochondrion (GO:0005739), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Sulfur amino acid metabolism	1
Metabolism of amino acids and derivatives	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
response to hypoxia	1
cellular response to stress	1
cellular response to decreased oxygen levels	1
transition metal ion binding	1
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	1
binding	1
catalytic activity	1
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen	1
dioxygenase activity	1
cation binding	1
oxidoreductase activity	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

346 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADO	CDO1	P78513	986
ADO	CSAD	Q9Y600	709
ADO	GADL1	Q6ZQY3	503
ADO	C3	P01024	425
ADO	SLC6A6	P31641	415
ADO	SCRN3	Q0VDG4	381
ADO	CTH	P32929	375
ADO	OGA	O60502	361
ADO	METAP1	P53582	348
ADO	EGR2	P11161	333
ADO	H7C2H4	H7C2H4	327
ADO	P0DN79	P0DN79	327
ADO	C1orf141	Q5JVX7	310
ADO	IL23R	Q5VWK5	266
ADO	CARS2	Q9HA77	263

IntAct

25 interactions, top by confidence:

A	B	Type	Score
CAP2	ADO	psi-mi:“MI:0915”(physical association)	0.560
ADO	DISC1	psi-mi:“MI:0915”(physical association)	0.560
FAM76B	ADO	psi-mi:“MI:0915”(physical association)	0.560
C5orf24	MEIS1	psi-mi:“MI:0914”(association)	0.530
TSSC4	SNRNP200	psi-mi:“MI:0914”(association)	0.530
ADO	RGS5	psi-mi:“MI:0945”(oxidoreductase activity electron transfer reaction)	0.440
ADO	RGS4	psi-mi:“MI:0945”(oxidoreductase activity electron transfer reaction)	0.440
FYCO1	RFT1	psi-mi:“MI:0914”(association)	0.350
KCNJ10	HSPA8	psi-mi:“MI:0914”(association)	0.350
ZNF212	ZNF746	psi-mi:“MI:0914”(association)	0.350
FAM76B	SORL1	psi-mi:“MI:0914”(association)	0.350
FCRL4	ADO	psi-mi:“MI:0914”(association)	0.350
SPANXN4	UBA6	psi-mi:“MI:0914”(association)	0.350
ANKRD39	UBA6	psi-mi:“MI:0914”(association)	0.350
STAC2	EIF1AX	psi-mi:“MI:0914”(association)	0.350
C16orf74	PPP3CC	psi-mi:“MI:0914”(association)	0.350
RTKN	ADO	psi-mi:“MI:0914”(association)	0.350
LRRC46	GTPBP6	psi-mi:“MI:0914”(association)	0.350
MFSD14A	FAM171A2	psi-mi:“MI:0914”(association)	0.350
ADO	CAP2	psi-mi:“MI:0915”(physical association)	0.000
ADO	DISC1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (26): ADO (Affinity Capture-MS), ADO (Affinity Capture-MS), ADO (Affinity Capture-MS), ADO (Affinity Capture-MS), ADO (Affinity Capture-MS), ADO (Affinity Capture-MS), ADO (Affinity Capture-MS), ADO (Affinity Capture-MS), ADO (Affinity Capture-MS), ADO (Two-hybrid), ADO (Two-hybrid), ADO (Negative Genetic), ADO (Affinity Capture-MS), ADO (Affinity Capture-RNA), ADO (Affinity Capture-MS)

ESM2 similar proteins: A0JMH0, A1YIZ1, B5DE73, B5DFG1, D3Z2R5, P13689, P33487, P33488, P33489, P33490, P33491, P68827, P97364, Q09200, Q0JCU7, Q10468, Q14703, Q3U487, Q53NI2, Q5E9N5, Q5EA24, Q5R673, Q5T447, Q5VW38, Q5YLM1, Q60649, Q6ICH7, Q6PDY2, Q6WQJ1, Q6Y290, Q6YRM6, Q86XS8, Q8CFC1, Q8IUF8, Q8IUH2, Q8IUL8, Q8NHY0, Q8VEM1, Q96375, Q96SZ5

Diamond homologs: Q556I2, Q6PDY2, Q96SZ5, Q9SJI9, Q1G3U6, Q8LGJ5, Q9LXG9, Q9LXT4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	25
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
152646	GRCh38/hg38 10q21.1-21.3(chr10:55287177-67558442)x3	Pathogenic
815349	GRCh37/hg19 10q21.1-21.3(chr10:56031210-65660398)x1	Pathogenic

SpliceAI

10 predictions. Top by Δscore:

Variant	Effect	Δscore
10:62806002:G:T	donor_gain	0.5500
10:62805854:TCCC:T	donor_gain	0.5400
10:62806002:G:GT	donor_gain	0.5000
10:62806041:A:AG	donor_gain	0.3200
10:62806034:C:T	donor_gain	0.2700
10:62804944:G:GA	donor_gain	0.2300
10:62806040:T:A	donor_gain	0.2300
10:62805837:G:GT	donor_gain	0.2000
10:62806038:GT:G	donor_gain	0.2000
10:62806039:TT:T	donor_gain	0.2000

AlphaMissense

1740 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:62805360:T:C	F101L	1.000
10:62805360:T:G	F101V	1.000
10:62805361:T:C	F101S	1.000
10:62805361:T:G	F101C	1.000
10:62805362:C:A	F101L	1.000
10:62805362:C:G	F101L	1.000
10:62805385:T:C	I109T	1.000
10:62805393:C:A	H112N	1.000
10:62805393:C:G	H112D	1.000
10:62805395:C:A	H112Q	1.000
10:62805395:C:G	H112Q	1.000
10:62805399:C:A	H114N	1.000
10:62805399:C:G	H114D	1.000
10:62805400:A:G	H114R	1.000
10:62805401:C:A	H114Q	1.000
10:62805401:C:G	H114Q	1.000
10:62805409:T:C	M117T	1.000
10:62805436:G:T	G126V	1.000
10:62805636:C:A	H193N	1.000
10:62805636:C:G	H193D	1.000
10:62805667:C:A	A203D	1.000
10:62805669:T:C	F204L	1.000
10:62805670:T:C	F204S	1.000
10:62805671:C:A	F204L	1.000
10:62805671:C:G	F204L	1.000
10:62805676:A:T	D206V	1.000
10:62805693:T:C	Y212H	1.000
10:62805717:T:C	C220R	1.000
10:62805718:G:A	C220Y	1.000
10:62805825:T:C	F256L	1.000

dbSNP variants (sampled 300 via entrez): RS1000279857 (10:62804726 C>T), RS1000337667 (10:62806446 G>A), RS1000666380 (10:62804875 G>A), RS1000823475 (10:62804739 T>C), RS1001685158 (10:62805035 C>T), RS1001737413 (10:62804857 A>C,G,T), RS1002743537 (10:62806190 A>G), RS1003564112 (10:62802966 G>A,C), RS1003663479 (10:62803172 CAAAA>C,CAAA,CAAAAA,CAAAAAAA,CAAAAAAAA), RS1003731016 (10:62807762 A>C), RS1004232850 (10:62806899 T>C), RS1004241752 (10:62805248 C>G,T), RS1004577712 (10:62804200 C>G,T), RS1004630073 (10:62804450 C>G,T), RS1004684683 (10:62806604 A>G)

Disease associations

OMIM: gene MIM:611392 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

29 associations (top):

Study	Trait	p-value
GCST001407_3	Ewing sarcoma	4.000000e-17
GCST001438_9	Crohn’s disease	7.000000e-09
GCST001585_31	Breast size	3.000000e-09
GCST001709_15	Atopic dermatitis	2.000000e-07
GCST002562_3	Vogt-Koyanagi-Harada syndrome	3.000000e-11
GCST003269_1	Cutaneous psoriasis	2.000000e-06
GCST003814_9	Selective IgA deficiency	7.000000e-07
GCST004131_20	Inflammatory bowel disease	2.000000e-36
GCST004132_12	Crohn’s disease	8.000000e-29
GCST004133_19	Ulcerative colitis	1.000000e-15
GCST004274_2	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)	5.000000e-06
GCST004625_179	Monocyte count	3.000000e-09
GCST004866_33	Alopecia areata	9.000000e-06
GCST005752_141	Systemic lupus erythematosus	7.000000e-06
GCST006020_30	Diastolic blood pressure	1.000000e-12
GCST006021_35	Systolic blood pressure	2.000000e-06
GCST006166_113	Diastolic blood pressure x alcohol consumption interaction (2df test)	2.000000e-13
GCST006227_9	Diastolic blood pressure	2.000000e-11
GCST006463_17	Urinary albumin excretion (no hypertensive medication)	1.000000e-08
GCST006586_28	Urinary albumin excretion	4.000000e-08
GCST007094_70	Diastolic blood pressure	1.000000e-15
GCST007099_231	Systolic blood pressure	1.000000e-11
GCST009640_13	Urinary albumin-to-creatinine ratio	8.000000e-10
GCST011494_53	Daytime nap	2.000000e-17
GCST012073_7	Behcet’s disease	3.000000e-08
GCST012465_59	Bipolar disorder	5.000000e-08
GCST90002388_558	Lymphocyte count	1.000000e-14
GCST90002393_354	Monocyte count	3.000000e-25
GCST90002402_117	Platelet count	7.000000e-17

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0007773	cutaneous psoriasis measurement
EFO:0005091	monocyte count
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure
EFO:0004329	alcohol drinking
EFO:0004285	albuminuria
EFO:0007778	urinary albumin to creatinine ratio
EFO:0007828	daytime rest measurement
EFO:0004587	lymphocyte count
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10995311	Efficacy	3	hydrochlorothiazide	Hypertension

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs10995311	ADO	3	3.00	1	hydrochlorothiazide

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
deguelin	increases expression	1
pyrachlostrobin	increases expression	1
picoxystrobin	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	increases methylation	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Estradiol	increases expression	1
Formaldehyde	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Rotenone	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Aflatoxin B1	decreases methylation	1
Gold Compounds	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1PK	HAP1 ADO (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.